Cosentyx is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking interleukin-17A (IL-17A), a protein that plays a key role in inflammation. According to the manufacturer's website [2], the recommended starting dose of Cosentyx for psoriasis is 300 mg given as two subcutaneous injections of 150 mg each at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 300 mg every 4 weeks. For psoriatic arthritis, the recommended starting dose is 150 mg or 300 mg given as two subcutaneous injections at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 150 mg or 300 mg every 4 weeks depending on the patient's response. The recommended starting dose for ankylosing spondylitis is 150 mg given as two subcutaneous injections at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 150 mg every 4 weeks [2].

According to a study published in the Journal of Clinical and Aesthetic Dermatology [3], the dosage of Cosentyx can be adjusted based on the patient's response. The study found that patients who did not respond to the standard maintenance dose of 300 mg every 4 weeks for psoriasis or 150 mg or 300 mg every 4 weeks for psoriatic arthritis could benefit from an increased dose of 300 mg every 2 weeks. However, the study also noted that the increased dose was associated with a higher risk of adverse events.

The frequency of Cosentyx dosage adjustments may vary depending on the patient's response to the medication. It is important for patients to work closely with their healthcare provider to determine the appropriate dosage and frequency of Cosentyx based on their individual needs and response to treatment.

Sources:
[2] https://www.cosentyx.com/psoriatic-arthritis/treatment-dosing
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422944/